GW Henssler & Associates Ltd. Raises Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)


Share on StockTwits

GW Henssler & Associates Ltd. grew its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 4.8% during the first quarter, Holdings Channel reports. The firm owned 19,362 shares of the biopharmaceutical company’s stock after acquiring an additional 883 shares during the quarter. GW Henssler & Associates Ltd.’s holdings in Regeneron Pharmaceuticals were worth $9,161,000 at the end of the most recent quarter.

A number of other large investors have also recently added to or reduced their stakes in the business. GFG Capital LLC lifted its stake in Regeneron Pharmaceuticals by 1.9% during the fourth quarter. GFG Capital LLC now owns 1,126 shares of the biopharmaceutical company’s stock worth $544,000 after purchasing an additional 21 shares in the last quarter. Grove Bank & Trust lifted its stake in Regeneron Pharmaceuticals by 2.1% during the fourth quarter. Grove Bank & Trust now owns 1,020 shares of the biopharmaceutical company’s stock worth $493,000 after purchasing an additional 21 shares in the last quarter. Haverford Trust Co. lifted its stake in Regeneron Pharmaceuticals by 5.5% during the fourth quarter. Haverford Trust Co. now owns 422 shares of the biopharmaceutical company’s stock worth $204,000 after purchasing an additional 22 shares in the last quarter. Wunderlich Capital Managemnt raised its stake in shares of Regeneron Pharmaceuticals by 0.5% in the fourth quarter. Wunderlich Capital Managemnt now owns 4,482 shares of the biopharmaceutical company’s stock valued at $2,165,000 after acquiring an additional 24 shares in the last quarter. Finally, Fieldpoint Private Securities LLC raised its stake in shares of Regeneron Pharmaceuticals by 5.2% in the fourth quarter. Fieldpoint Private Securities LLC now owns 506 shares of the biopharmaceutical company’s stock valued at $244,000 after acquiring an additional 25 shares in the last quarter. Institutional investors own 85.00% of the company’s stock.

REGN traded down $6.29 during trading on Tuesday, reaching $482.33. The company’s stock had a trading volume of 16,642 shares, compared to its average volume of 980,126. Regeneron Pharmaceuticals, Inc. has a 52-week low of $441.00 and a 52-week high of $664.64. The company’s fifty day moving average price is $482.38 and its 200-day moving average price is $503.31. The company has a market capitalization of $51.67 billion, a price-to-earnings ratio of 17.61, a price-to-earnings-growth ratio of 0.82 and a beta of 0.30. The company has a debt-to-equity ratio of 0.27, a quick ratio of 3.12 and a current ratio of 3.89.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings data on Thursday, February 4th. The biopharmaceutical company reported $9.53 earnings per share for the quarter, beating the Zacks’ consensus estimate of $7.11 by $2.42. Regeneron Pharmaceuticals had a return on equity of 28.97% and a net margin of 38.28%. The company had revenue of $2.42 billion for the quarter, compared to analyst estimates of $2.40 billion. During the same quarter in the previous year, the company earned $7.50 EPS. The firm’s revenue for the quarter was up 11.7% compared to the same quarter last year. Equities analysts predict that Regeneron Pharmaceuticals, Inc. will post 27.23 earnings per share for the current year.

Several analysts have recently issued reports on REGN shares. Robert W. Baird reiterated a “hold” rating on shares of Regeneron Pharmaceuticals in a research note on Tuesday, April 13th. BMO Capital Markets upgraded Regeneron Pharmaceuticals from a “market perform” rating to an “outperform” rating and set a $630.00 price objective on the stock in a research note on Monday, January 25th. Canaccord Genuity reiterated a “buy” rating on shares of Regeneron Pharmaceuticals in a research note on Tuesday, April 13th. Cantor Fitzgerald cut their price target on Regeneron Pharmaceuticals from $696.00 to $656.00 and set an “overweight” rating on the stock in a research note on Tuesday, February 16th. Finally, SVB Leerink raised their price target on Regeneron Pharmaceuticals from $655.00 to $657.00 and gave the company an “outperform” rating in a research note on Thursday, April 1st. Five investment analysts have rated the stock with a hold rating, fourteen have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average price target of $644.17.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various medical conditions worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion.

Further Reading: Beige Book

Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN).

Institutional Ownership by Quarter for Regeneron Pharmaceuticals (NASDAQ:REGN)

Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.